ReviewAntibiotics (Basel, Switzerland)2021
Mucormycosis in Indian COVID-19 Patients: Insight into Its Patho-Genesis, Clinical Manifestation, and Management Strategies.
Review in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Breakthrough mucormycosis after hematopoietic stem cell transplantation: a retrospective multiyear cohort study in Eastern China.Annals of clinical microbiology and antimicrobials · 2026Observational
- Molecular Mechanisms of Mucormycosis Pathogenesis: Host-Pathogen Interactions and Immune Evasion.Pathogens (Basel, Switzerland) · 2026Review
- Clinical profile and outcome of COVID-19 associated mucormycosis in Shiraz, South Iran: a longitudinal study.Iranian journal of microbiology · 2026Article
- Comparative Mortality and Risk Analysis in Mucormycosis Cases: Pre-Pandemic Versus COVID-19 Association.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025Article
- Intensification of Invasive Fungal Infections and Exploration of Effective Antifungal Drug Delivery Formulations: A Detailed Review.Infectious disorders drug targets · 2025Review
- Mucormycosis: A Rare disease to Notifiable Disease.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Review
- Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review.Frontiers in immunology · 2023Review
- Global Emergence of Resistance to Fluconazole and Voriconazole inOpen forum infectious diseases · 2022Article
- Rhino-orbital-cerebral mucormycosis as a complication of coronavirus disease 2019.World journal of virology · 2022Review
- Mucormycosis in pre-COVID-19 and COVID-19 era: A study of prevalence, risk factors and clinical features.Laryngoscope investigative otolaryngology · 2022Article
- Bronchial wall necrosis secondary to mucormycosis following SARS-Cov2 infection: A case report.Radiology case reports · 2022Article
- Review
- Mucormycosis and COVID-19-Associated Mucormycosis: Insights of a Deadly but Neglected Mycosis.Journal of fungi (Basel, Switzerland) · 2022Review
- Management of coronavirus disease (Covid-19) associated mucormycosis with palatal ulcer, dental pain and anterior maxillary teeth mobility- A clinical dilemma of Covid 19 pandemic in India.Journal of family medicine and primary care · 2022Article
- Study of Management of Mucormycosis in COVID and Post-COVID Patients with Liposomal Amphotericin B its Outcome and Complications in a dedicated COVID Hospital from Eastern India.Nigerian medical journal : journal of the Nigeria Medical AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 4 countries.
Funding
Abstract
Mucormycosis in patients who have COVID-19 or who are otherwise immunocompromised has become a global problem, causing significant morbidity and mortality. Infection is debilitating and fatal, leading to loss of organs and emotional trauma. Radiographic manifestations are not specific, but diagnosis can be made through microscopic examination of materials collected from necrotic lesions. Treatment requires multidisciplinary expertise, as the fungus enters through the eyes and nose and may even reach the brain. Use of the many antifungal drugs available is limited by considerations of resistance and toxicity, but nanoparticles can overcome such limitations by reducing toxicity and increasing bioavailability. The lipid formulation of amphotericin-B (liposomal Am-B) is the first-line treatment for mucormycosis in COVID-19 patients, but its high cost and low availability have prompted a shift toward surgery, so that surgical debridement to remove all necrotic lesions remains the hallmark of effective treatment of mucormycosis in COVID-19. This review highlights the pathogenesis, clinical manifestation, and management of mucormycosis in patients who have COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.